The FDA is weighing whether to downgrade the risk classification of electroshock devices used to treat major depression and other diseases, thus allowing devicemakers to introduce new products without costly clinical tests. Advocates say the treatment is much safer than it's been in the past, while opponents worry that the procedure causes memory loss and brain damage. An FDA advisory panel will review the proposal this week, according to the New York Times. Report